Levonorgestrel intrauterine contraceptive systems (13.5 mg and 52 mg) and risk of ectopic pregnancy

被引:7
|
作者
Graner, Sofie [1 ,2 ]
Mc Taggart, Julia [3 ]
Nordstrom, Fanny [3 ]
Melander, Emma [3 ]
Widenberg, Johan [4 ]
Kallner, Helena Kopp [3 ,4 ,5 ]
机构
[1] Karolinska Inst, Karolinska Univ Hosp, Dept Med, Ctr Pharmacoepidemiol, Stockholm, Sweden
[2] Danderyd Hosp, Matern BB Stockholm, Stockholm, Sweden
[3] Karolinska Inst, Danderyd Hosp, Dept Clin Sci, Stockholm, Sweden
[4] Danderyd Hosp, Dept Obstet & Gynecol, Stockholm, Sweden
[5] Karolinska Inst, Dept Womens & Childrens Hlth, Stockholm, Sweden
关键词
Ectopic pregnancy; intrauterine contraception; levonorgestrel containing intrauterine system; levonorgestrel containing intrauterine system 13; 5; mg; levonorgestrel containing intrauterine system 52 mg; Pearl index; LNG-IUS; 8; PHASE-III; SINGLE-ARM; MULTICENTER; PROGESTASERT; SAFETY;
D O I
10.1111/aogs.13564
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Introduction The objective was to investigate the Pearl index for ectopic pregnancy in women using the levonorgestrel intrauterine system (LNG-IUS) at the time of conception. Material and methods This was a substudy of a hospital-based historical cohort including women with an ectopic pregnancy diagnosed in 4 referral hospitals in Stockholm, Sweden between December 2013 and April 2017. Study participants and type of contraception at time of conception were identified through the electronic medical chart system. Cases were defined as women with LNG-IUS 13.5 or 52 mg in situ at the time of diagnosis of ectopic pregnancy who had their LNG-IUS inserted 1 January 2014 or later. Outcome was defined as the incidence rate for ectopic pregnancy during use per 100 woman-years (Pearl index) with 95% confidence interval (95% CI). Results The study includes 35 cases with LNG-IUS 13.5 mg and 13 cases with LNG-IUS 52 mg, which occurred in 18 488 (13.5 mg) and 50 246 (52 mg) exposed woman-years. Pearl index for ectopic pregnancy was estimated at 0.19 (95% CI 0.15-0.28) for LNG-IUS 13.5 mg and to 0.006 (95% CI 0.00-0.01) for LNG-IUS 52 mg. The most cases for the LNG-IUS 13.5 mg (n = 26; 74%) occurred during the first year of use with a corresponding Pearl index at 0.23 (95% CI 0.14-0.35). Conclusions The absolute risk of ectopic pregnancy during the use of LNG-IUS remains low. Our method may underestimate as well as overestimate the Pearl index for ectopic pregnancy. The findings underline the importance of identifying risk factors for ectopic pregnancy at insertion, and to rule out ectopic pregnancy for all women presenting with abdominal discomfort during the use of LNG-IUS. Longer observation periods and prospective studies in a general population are a priority for further research.
引用
收藏
页码:937 / 943
页数:7
相关论文
共 50 条
  • [1] The 13.5-mg, 19.5-mg, and 52-mg Levonorgestrel-Releasing Intrauterine Systems and Risk of Ectopic Pregnancy
    Elgemark, Karin
    Graner, Sofie
    McTaggart, Julia
    Lofstrom, Jennie Ramirez
    Sorensen, Daniela
    Envall, Niklas
    Kallner, Helena Kopp
    OBSTETRICS AND GYNECOLOGY, 2022, 140 (02): : 227 - 233
  • [2] Ectopic Pregnancy Risk in Users of Levonorgestrel-Releasing Intrauterine Systems With 52, 19.5, and 13.5 mg of Hormone
    Meaidi, Amani
    Torp-Pedersen, Christian
    Lidegaard, Ojvind
    Morch, Lina Steinrud
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2023, 329 (11): : 935 - 937
  • [3] Comparing bleeding patterns for the levonorgestrel 52 mg, 19.5 mg, and 13.5 mg intrauterine systems
    Goldthwaite, Lisa M.
    Creinin, Mitchell D.
    CONTRACEPTION, 2019, 100 (02) : 128 - 131
  • [4] Rate of and Reason for Discontinuation of Levonorgestrel 13.5 mg Intrauterine System as Compared to Levonorgestrel 52 mg Intrauterine System and Subsequent Contraceptive Choice at an Academic Medical Center
    Cope, Adela G.
    Weaver, Amy L.
    Casey, Petra M.
    JOURNAL OF REPRODUCTIVE MEDICINE, 2020, 65 (7-8) : 231 - 239
  • [5] 52 mg Levonorgestrel Intrauterine System as a Long-Term Contraceptive Option
    Ferguson, Dewonna
    Pejic, Jelena
    Shihab, Sara
    Vegunta, Suneela
    JOURNAL OF WOMENS HEALTH, 2025, 34 (04) : 578 - 579
  • [6] Ectopic Pregnancy Risk and Levonorgestrel-Releasing Intrauterine Systems
    Jugl, Sebastian
    Winterstein, Almut G.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2023, 330 (04):
  • [7] Five-Year Contraceptive Efficacy and Safety of a Levonorgestrel 52-mg Intrauterine System
    Teal, Stephanie B.
    Turok, David K.
    Chen, Beatrice A.
    Kimble, Thomas
    Olariu, Andrea, I
    Creinin, Mitchell D.
    OBSTETRICS AND GYNECOLOGY, 2019, 133 (01): : 63 - 70
  • [8] Six-year contraceptive efficacy and continued safety of a levonorgestrel 52 mg intrauterine system
    Westhoff, Carolyn L.
    Keder, Lisa M.
    Gangestad, Angelina
    Teal, Stephanie B.
    Olariu, Andrea I.
    Creinin, Mitchell D.
    CONTRACEPTION, 2020, 101 (03) : 159 - 161
  • [9] Ectopic Pregnancy Risk and Levonorgestrel-Releasing Intrauterine Systems Reply
    Meaidi, Amani
    Torp-Pedersen, Christian
    Morch, Lina Steinrud
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2023, 330 (04): : 378 - 379
  • [10] The levonorgestrel-releasing intrauterine system 52 mg as a contraceptive versus a therapeutic: essential differences and perspectives
    Goldstuck, Norman D. D.
    EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE, 2023, 28 (03): : 177 - 183